Drugs / Nab-placlitaxel
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06449222 | Aug 2024 → Aug 2028 expected | female breast carcinoma, triple-negative breast carcinoma | BioNTech SE | Active not recruiting | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Nab-placlitaxel | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06449222 ↗ |